A profile of Smile Train, the world’s largest cleft organization, kicks off the 22nd season of The Visionaries, an award-winning public television series, hosted by acclaimed actor Sam Waterston. The Visionaries documentary series highlights the stories of individuals and nonprofit organizations that are working to create positive social change throughout the world. Visionaries has selected Smile Train to be profiled because the organization’s impact represents a unique opportunity to explore the seldom discussed issue of “appearance” in human society.
The Visionaries series takes viewers around the world to experience the lives of extraordinary people tackling some of humanity’s toughest challenges. The series guides viewers on a journey that leads to real solutions with proven outcomes, many of which have the potential to change the world.
To view the multimedia release go to:
https://www.multivu.com/players/English/8293751-smile-train-the-visionaries-documentary-pbs-series/
West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
Cutanea Life Sciences, Inc. (CLS), an emerging U.S. prescription product development company, formally unveiled its new digital presence, www.cutanea.com, to the dermatology community in conjunction with this winter’s annual gathering of dermatologists from the U.S and around the world. CLS has a stream of innovative product candidates in different stages of development that cover an array of skin conditions, including acne, rosacea, psoriasis and warts caused by human papillomavirus (HPV).
CLS’s new digital presence demonstrates the company’s intent to change the way that customers think about a valued dermatology partner. CLS believes that it can make an impact in the current state of dermatology practice through its commitment to focus on unmet and underserved patient needs. In turn this will help medical professionals optimize their practice time through CLS products and services.
To view the multimedia release go to:
http://www.multivu.com/players/English/7743651-cutanea-life-sciences-dermatology/
St. Jude Children’s Research Hospital patients who completed kindergarten during their treatment for pediatric cancers celebrated at a graduation ceremony.
For the 10th straight year, St. Jude honored 14 patients from around the United States who completed kindergarten while battling life-threatening illnesses like leukemia and brain tumors. Dozens of families and St. Jude doctors, nurses, and staff cheered for the young students, who completed kindergarten in the St. Jude School Program by Chili’s.
Each year, the school program commemorates students who have completed kindergarten coursework with a special ceremony. The children present a song for the families and St. Jude staff, receive their diplomas and celebrate the milestone with their fellow students.
To view the multimedia release go to:
https://www.multivu.com/players/English/7924755-st-jude-celebrates-kindergarten-graduation/
Today, Church & Dwight, Co., Inc., the makers of First Response™ pregnancy and ovulation tests, announced the launch of First Response™ Pregnancy PRO Digital Pregnancy Test & App Access – their latest innovation and the first and only Bluetooth Smart-enabled pregnancy test on the market. First Response™ Pregnancy PRO connects to a woman’s smart device through a mobile application. Once synced, the app provides her with pregnancy-related content only available with Pregnancy PRO, and delivers a personalized user experience throughout her entire pregnancy journey.
“We are thrilled to be unveiling the next generation of in-home pregnancy testing on a stage like CES, where so many technological advancements have made their debut,” said Stacey Feldman, Vice President of Marketing, Church & Dwight. “With Pregnancy PRO, we’ve leveraged unique consumer insights to develop a product that not only revolutionizes the pregnancy test category, but more importantly, provides women with the information they need during their journey.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7725251-first-response-pregnancy-pro/
Breast cancer now represents one in four of all cancers in women worldwide and touches lives every day. While experiences with the disease may vary, the desire to defeat breast cancer is universal. This year, in honor of a shared vision for a world without this disease, The Estée Lauder Companies’ Breast Cancer Awareness (BCA) Campaign celebrates the power of global solidarity by encouraging people around the world to “Take Action Together to Defeat Breast Cancer.” The 2016 BCA Campaign invites women, men and families to draw inspiration from one another and unite in action on BCAcampaign.com and social media, while supporting lifesaving breast cancer research.
Over the past two decades, The Estée Lauder Companies’ BCA Campaign, launched by the late Evelyn H. Lauder, co-creator of the Pink Ribbon and founder of the Breast Cancer Research Foundation® (BCRF), has been a leading voice for breast cancer awareness around the world, igniting a global movement that has helped save millions of lives and fund innovative breast cancer research. Today, The BCA Campaign is active in more than 70 countries and has raised more than $65 million to support global research, education and medical services, with more than $50 million funding 200 BCRF medical research grants worldwide over the past 22 years. These funds help accelerate critical research across wide-ranging areas such as tumor biology, heredity and ethnicity, lifestyle and prevention, treatment, survivorship and metastasis. Around the world, The BCA Campaign partners with more than 60 breast cancer organizations focused on breast cancer research, education and medical services. This year, The BCA Campaign is committed to raising $6 million in support of its mission to defeat breast cancer through education and medical research.
To view the multimedia release go to:
http://www.multivu.com/players/English/7935851-estee-lauder-bca-campaign-2016/
Blood cancers are the third leading cause of cancer deaths in the U.S. However, many Americans are unaware of the impact of these cancers, including leukemia, lymphoma and myeloma, which affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system.
A new survey commissioned by The Leukemia & Lymphoma Society (LLS) reveals more than four in five adults (82%) are surprised that blood cancers are the third leading cancer killer of Americans. Further, nearly four in five adults (78%) are surprised that acute lymphocytic leukemia (ALL) is the most common cancer in children and young adults under age 20.
To view the multimedia release go to:
https://www.multivu.com/players/English/8128551-lls-blood-cancer-awareness-month/
Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.
“The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV,” said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. “It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7560331-time-to-talk-cinv/
Ethicon*, a trusted leader in advancing wound closure, announces the launch of STRATAFIX™ Spiral PDS Plus and STRATAFIX™ Spiral Monocryl Plus Knotless Tissue Control Devices. With the addition of these two new suture technologies to the STRATAFIX™ Family of Knotless Tissue Control Devices, Ethicon has established the most comprehensive and unmatched knotless suture offering available to surgeons in the U.S.
STRATAFIX™ Knotless Tissue Control Devices transforms the wound closure experience by providing unique advantages over traditional sutures. STRATAFIX™ sutures provide more strength and security, more consistency and more efficiency than traditional suturing. The portfolio of knotless sutures also enables surgeons to more easily manage tension and control tissue approximation with each pass during closure and eliminates the need to tie knots.
To view the multimedia release go to:
http://www.multivu.com/players/English/7889651-ethicon-new-stratafix-suture/
FAIR Health has launched a groundbreaking website, YouCanPlanForThis.org, aimed at transforming how people in New York State engage in healthcare planning. A next-generation transparency tool, the free site gives New Yorkers unprecedented access to accurate medical and dental costs and comprehensive educational resources, so they can plan financially for a procedure or episode of care. A national, independent, nonprofit organization dedicated to bringing transparency to healthcare costs and health insurance information, FAIR Health developed YouCanPlanForThis.org by building on its existing, award-winning consumer website and mobile app, with the support of the New York State Health Foundation (NYSHealth).
To view the multimedia release go to:
https://www.multivu.com/players/English/8087151-fair-health-youcanplanforthis-healthcare-planning/
Kaléo, a privately-held pharmaceutical company, today announced the AUVI-Q® (epinephrine injection, USP) Auto-injector will be available by prescription starting February 14th, and announced AUVI-Q AffordAbility, a first-of-its-kind access program for AUVI-Q. Through this new program, patients with commercial insurance, even those with high-deductible plans, will have an out-of-pocket cost of $0. For patients who do not have government or commercial insurance, and have a household income of less than $100,000, AUVI-Q will be available free of charge. In addition, the cash price for AUVI-Q is $360 and will be available to those patients without government or commercial insurance. Each AUVI-Q prescription includes two Auto-injectors and one Trainer for AUVI-Q.
To view the multimedia release go to:
http://www.multivu.com/players/English/7981051-auvi-q-epinephrine-auto-injector-access-and-availability-launch/
Institut Marquès presents the 1000th birth of its international embryo adoption programme. It is a baby girl called Georgina who, with 3,500 kg. of weight, was born in the town of Essex (UK) last February. Her mother decided to adopt an embryo at Institut Marquès, a clinic in Barcelona, after having performed several cycles of assisted reproduction without success in different centres. In June, an embryo that had been frozen for years was transferred; it came from the treatment of a couple who did not answer about the destination they wanted for their embryos and they were thus left under the custody of the clinic.
Kerry Andersen, Georgina's mother, is a midwife. A 45-year-old single woman who believes that this treatment has given her "the best of my life, which was the hope of being a mother. I am thrilled to think that my precious daughter is here thanks to the embryo adoption programme as I feel it is a very special way to enjoy motherhood. When I got to know this program, I did not hesitate to adopt an embryo”.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8112351-institut-marques-women-spain-adopt-embryos/
